Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Metsera
Developing next-gen obesity therapies
Biotech
Metsera follows phase 1 weight loss data with $215M series B
Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in a hefty $215 million series B fundraise.
James Waldron
Nov 13, 2024 9:15am
Prothena promotes one exec while another leaves—Chutes & Ladders
Oct 4, 2024 8:00am
Metsera allies with Amneal to lock down GLP-1 supply
Oct 1, 2024 6:01am
Arch closes $3B-plus fund to foster biopharma upstarts
Sep 26, 2024 10:24am
Metsera GLP-1 data slice reveals 7.5% weight loss at 36 days
Sep 24, 2024 7:00am
